| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
|
|
|
||||||
|
||||||||
Journal Article |
Department of Pathology, Haartman Institute, Helsinki University Central Hospital, FIN-00014 University of Helsinki, Haartmaninkatu 3, Helsinki, Finland.
BACKGROUND AND OBJECTIVES: Translocation-associated gene fusions are well recognized in acute myeloid leukemia. Other molecular genetic changes are less well known. The novel cDNA technology has opened the avenue to large-scale gene expression analysis. Our aim was to perform cDNA microarray analysis of acute myeloid leukemia (AML). DESIGN AND METHODS: We performed cDNA microarray analysis using the Clontech hematology filter (containing 406 genes) on 15 patients to study gene expression profiling in AML. As reference, we used whole bone marrow from 5 healthy donors. RESULTS: Our results revealed 50 differentially expressed genes in at least 3 out of 15 patients. Twenty-two genes were upregulated (ratio > or =4), whereas 28 genes were downregulated (ratio < or =0.25). All but one of the 13 genes tested by real-time polymerase chain reaction (PCR) showed the same expression profiles. Among the overexpressed genes, several were those earlier associated with chromosomal translocations and gene fusions. These genes were FGFR1, MYC, NPM1, DEC, and BCL2. The expression of two upregulated genes, HOXA4 and CSF1R, was significantly higher in patients with a white blood cell count higher than 30 x 10(9)/L cells. In patients whose white blood cell count was higher than 100 x 10(9)/L cells, both CLC and GRN were significantly underexpressed, whereas HOXA4 and DAPK1 were overexpressed. FGFR1 and CAMLG were more frequently significantly overexpressed in patients with CD56 immunophenoytpe. INTERPRETATION AND CONCLUSIONS: Clinical and prognostic significance of differential gene expression should be studied with a larger series of patients by using other techniques, such as quantitative real-time PCR.
This article has been cited by other articles:
|
|
 |
|
  T. M. Wise-Draper, R. A. Mintz-Cole, T. A. Morris, D. S. Simpson, K. A. Wikenheiser-Brokamp, M. A. Currier, T. P. Cripe, G. C. Grosveld, and S. I. Wells Overexpression of the Cellular DEK Protein Promotes Epithelial Transformation In vitro and In vivo Cancer Res., March 1, 2009; 69(5): 1792 - 1799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Mor-Vaknin, A. Punturieri, K. Sitwala, N. Faulkner, M. Legendre, M. S. Khodadoust, F. Kappes, J. H. Ruth, A. Koch, D. Glass, et al. The DEK Nuclear Autoantigen Is a Secreted Chemotactic Factor Mol. Cell. Biol., December 15, 2006; 26(24): 9484 - 9496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Wise-Draper, H. V. Allen, E. E. Jones, K. B. Habash, H. Matsuo, and S. I. Wells Apoptosis Inhibition by the Human DEK Oncoprotein Involves Interference with p53 Functions Mol. Cell. Biol., October 15, 2006; 26(20): 7506 - 7519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Wise-Draper, H. V. Allen, M. N. Thobe, E. E. Jones, K. B. Habash, K. Munger, and S. I. Wells The Human DEK Proto-Oncogene Is a Senescence Inhibitor and an Upregulated Target of High-Risk Human Papillomavirus E7 J. Virol., November 15, 2005; 79(22): 14309 - 14317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Cleary, K. V. Sitwala, M. S. Khodadoust, R. P. S. Kwok, N. Mor-Vaknin, M. Cebrat, P. A. Cole, and D. M. Markovitz p300/CBP-associated Factor Drives DEK into Interchromatin Granule Clusters J. Biol. Chem., September 9, 2005; 280(36): 31760 - 31767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Schwable, C. Choudhary, C. Thiede, L. Tickenbrock, B. Sargin, C. Steur, M. Rehage, A. Rudat, C. Brandts, W. E. Berdel, et al. RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation Blood, March 1, 2005; 105(5): 2107 - 2114. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
